[{"id":"c67cb0cc-4062-4cc7-ac4c-e0358ba638bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT06986174","created_at":"2025-06-28T16:12:40.055Z","updated_at":"2025-06-28T16:12:40.055Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","source_id_and_acronym":"NCT06986174","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" MYD88 • CXCR4","pipe":" | ","alterations":" TP53 mutation","tags":["MYD88 • CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2025-05-22"},{"id":"f4b4cbe0-4811-4846-aa3a-c12b65f5b2a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052618","created_at":"2023-09-25T14:10:30.120Z","updated_at":"2025-02-25T12:29:50.276Z","phase":"Phase 2","brief_title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","source_id_and_acronym":"NCT06052618","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 01/01/2033","primary_completion_date":" 01/01/2033","study_txt":" Completion: 01/01/2034","study_completion_date":" 01/01/2034","last_update_posted":"2025-02-24"},{"id":"9b0dc769-7e69-4597-ba4b-209925af9306","acronym":"","url":"https://clinicaltrials.gov/study/NCT02891603","created_at":"2021-01-18T14:11:34.890Z","updated_at":"2024-07-02T16:35:12.946Z","phase":"Phase 1/2","brief_title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","source_id_and_acronym":"NCT02891603","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IL6 • HLA-DRB1 • CD4 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/08/2017","start_date":" 06/08/2017","primary_txt":" Primary completion: 01/28/2022","primary_completion_date":" 01/28/2022","study_txt":" Completion: 04/18/2022","study_completion_date":" 04/18/2022","last_update_posted":"2024-03-25"},{"id":"ef2d8abd-fb23-45a9-a65d-be237a4a3a82","acronym":"","url":"https://clinicaltrials.gov/study/NCT02515630","created_at":"2021-01-20T23:56:21.590Z","updated_at":"2024-07-02T16:35:45.372Z","phase":"Phase 2","brief_title":"Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","source_id_and_acronym":"NCT02515630","lead_sponsor":"Sierra Oncology LLC - a GSK company","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojjaara (momelotinib)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/29/2016","start_date":" 01/29/2016","primary_txt":" Primary completion: 07/18/2017","primary_completion_date":" 07/18/2017","study_txt":" Completion: 08/15/2017","study_completion_date":" 08/15/2017","last_update_posted":"2023-06-19"},{"id":"22923149-06d3-45f2-a2f9-f7f680b159a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00794781","created_at":"2021-01-18T03:00:59.393Z","updated_at":"2024-07-02T16:36:02.453Z","phase":"Phase 1","brief_title":"A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT00794781","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E6201"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/22/2008","start_date":" 06/22/2008","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 10/15/2015","study_completion_date":" 10/15/2015","last_update_posted":"2022-10-14"},{"id":"9d13b4e5-4447-44e1-af76-2327291df5eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04520269","created_at":"2021-01-18T21:39:11.365Z","updated_at":"2024-07-02T16:36:41.807Z","phase":"Phase 1/2","brief_title":"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)","source_id_and_acronym":"NCT04520269","lead_sponsor":"National University Hospital, Singapore","biomarkers":" S100A8","pipe":"","alterations":" ","tags":["S100A8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vonjo (pacritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2020-08-20"},{"id":"f1d383d7-f92a-48bb-8f87-409a8f8ac1fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02323607","created_at":"2021-01-18T11:01:13.502Z","updated_at":"2024-07-02T16:37:03.486Z","phase":"Phase 1","brief_title":"Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations","source_id_and_acronym":"NCT02323607","lead_sponsor":"Bhavana Bhatnagar","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • daunorubicin • Vonjo (pacritinib)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/12/2016","start_date":" 01/12/2016","primary_txt":" Primary completion: 07/12/2018","primary_completion_date":" 07/12/2018","study_txt":" Completion: 07/12/2018","study_completion_date":" 07/12/2018","last_update_posted":"2019-01-25"}]